USANew treatments and approvals
Prademagene zamikeracel receives FDA approval for wounds in butterfly skin disease (RDEB)
A decision by a medicines regulator (FDA, European Commission, etc.). The regulator has reviewed the clinical studies behind the drug. For accelerated or conditional approvals, the lasting benefit is still being confirmed.
The FDA has approved prademagene zamikeracel for wounds in patients with recessive dystrophic epidermolysis bullosa. In the treatment, the patient's own skin cells are genetically corrected. This way, the cells produce the missing collagen VII protein. The cells are surgically applied as sheets onto chronic wounds. In a phase 3 study, healing was seen in 81% of treated wounds. These wounds healed by at least half within 6 months.
What does it mean for patients and families?
A new option has become available for patients with chronic, non-healing wounds. This is a cell-based gene therapy. Access in Türkiye depends on TİTCK (Turkish Medicines and Medical Devices Agency) and SGK (Social Security Institution) processes.
Source
AJMC: FDA Approves Prademagene Zamikeracel for Recessive Dystrophic Epidermolysis Bullosa
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Epidermolysis bullosa (butterfly skin disease)
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.